Inflection Biosciences Ltd, a private company focused on the development of targeted small molecule treatments for cancer, today announced that it has entered into a license agreement with the Spanish National Cancer Research Centre (CNIO) for the exclusive, worldwide rights to develop and commercialise several novel kinase inhibitors for the treatment of cancer.
The compounds leverage the CNIO’s considerable expertise in drug discovery and comprise a novel pan-PIM kinase inhibitor program and a number of unique multi-targeting kinase inhibitors combining activity on PIM kinase and additional kinases including the phosphoinositide-3 kinase and the mammalian target of rapamycin (PI3K/mTOR) pathway. All molecules have shown good activity in preclinical models, are orally-available with excellent pharmaceutical properties.
Dr Michael O’Neill, Co-Founder and Director of Research and Development at Inflection Biosciences commented “Following an extensive global search we are delighted to have secured assets in late preclinical stages of development of this quality and potential and from an organisation recognised internationally for the quality of its cancer research and its drug discovery programs.”
Dr María Blasco, Director of CNIO added “It is a great satisfaction for the CNIO to join forces with the experienced team at Inflection Biosciences, allowing us to take full advantage of our ability to innovate cancer treatments.”
Inflection Biosciences and CNIO will collaborate in the conduct of additional preclinical studies on the programs to further profile the potential treatments. Inflection Biosciences will have responsibility for nominating lead candidates and for onward development.
Inflection Biosciences further announced today that it has secured its first financing round from a private investor and Enterprise Ireland. The funds raised will primarily be used to advance the Company’s development pipeline.
“We are grateful to our investors for sharing our vision to make a real contribution to the development of important new treatments for patients suffering with cancer.” commented Co-Founder and Chief Executive Officer of Inflection Biosciences, Darren Cunningham.
Dr Brian O’Neill, Manager, High Potential Start-Ups, Industrial & Lifesciences at Enterprise Ireland added “Inflection Biosciences is a great example of an early stage technology company with a highly experienced team that is leveraging the resources and discovery expertise of the leading global research institutes to commercialise innovative treatments for cancer. The Inflection Biosciences’ approach to drug development offers enormous potential by bringing some of the best research the world can offer into Ireland, a country recognised for fostering and funding innovation led ventures. Enterprise Ireland is delighted to support this high potential start up business.”